Arni Blöndal

Axelyf was founded in Iceland in 2022 with the goal of harnessing health benefits of natural molecules through chemistry and delivery engineering.

hopp is an electric scooter sharing service & micromobility SaaS solution founded in Iceland. We provide small business owners around the world the opportunity to launch their own e-scooter franchise business in their local area. Our goal is to be the global leader in sustainable urban transportation in small cities all over the world. For more information on launching your own franchise, please visit our website: https://hopp.bike/franchise

Laki Power is a leader in real-time, operational intelligence and analytics for high-voltage power grids. Our unique line monitoring solutions enhance the ability of transmission and distribution system operators to meet the challenges of optimised performance, reduced cost, increased safety, as well as better security and resilience.

We are a self-serve influencer platform that enables brands and agencies to create on-demand influencer campaigns, anywhere in the world. The Ghostlamp platform automates the process of finding, contracting and paying influencers giving you the power to start a movement in minutes. On Ghostlamp you purchase real impact for your brand measured in EPIC, not a number of influencers or pieces of content. EPIC is a unified engagement metric for all social channels. We guarantee the EPIC impact you purchase. Ghostlamp also measures the success of your campaigns and keeps track of all the influencer generated content. Ghostlamp has proven itself as an exceptional solution for brands and agencies looking to launch influencer campaigns in the fast moving consumer goods (FMCG) sector. Contact info@ghostlamp.com and let's setup your campaign today.

Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’ highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis’ goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.

DTE, a global company, based in Reykjavik, Iceland, is the leading innovator in the field of real-time intelligence from liquid metals by combining connected, real-time, chemical composition analysis from molten metals -based on DTE's unique technology Liquid-Phase, Laser-Induced Breakdown Spectroscopy (LP-LIBS™)- with an artificial intelligence-based cloud platform, the engine of DTE's metals production ecosystem. DTE's vision is to transform the metals industry, contributing to the 1.5-degree challenge while driving its digital transformation towards Industry 4.0 with the next generation of elemental analysis technology and metals intelligence. The Company's elemental analyzers provide first-in-industry direct sampling and compositional analysis of molten metal, addressing the high unmet need to complement and replace current inefficient, unsafe, and error-prone manual methods for process and quality control with real-time analysis of trace elements. DTE's artificial intelligence based-cloud platform is the cornerstone of the solution providing the industry ecosystem for all the stakeholders to maximize the value from the chemical composition analysis from liquid metal. The platform provides real-time actionable intelligence to maximize benefits along the value chain by breaking silos, providing information in context, monetizing information, delivering predictive insights for forward-looking process control and business decisions, and driving change.

Axelyf was founded in Iceland in 2022 with the goal of harnessing health benefits of natural molecules through chemistry and delivery engineering.

hopp is an electric scooter sharing service & micromobility SaaS solution founded in Iceland. We provide small business owners around the world the opportunity to launch their own e-scooter franchise business in their local area. Our goal is to be the global leader in sustainable urban transportation in small cities all over the world. For more information on launching your own franchise, please visit our website: https://hopp.bike/franchise

Laki Power is a leader in real-time, operational intelligence and analytics for high-voltage power grids. Our unique line monitoring solutions enhance the ability of transmission and distribution system operators to meet the challenges of optimised performance, reduced cost, increased safety, as well as better security and resilience.

We are a self-serve influencer platform that enables brands and agencies to create on-demand influencer campaigns, anywhere in the world. The Ghostlamp platform automates the process of finding, contracting and paying influencers giving you the power to start a movement in minutes. On Ghostlamp you purchase real impact for your brand measured in EPIC, not a number of influencers or pieces of content. EPIC is a unified engagement metric for all social channels. We guarantee the EPIC impact you purchase. Ghostlamp also measures the success of your campaigns and keeps track of all the influencer generated content. Ghostlamp has proven itself as an exceptional solution for brands and agencies looking to launch influencer campaigns in the fast moving consumer goods (FMCG) sector. Contact info@ghostlamp.com and let's setup your campaign today.

Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’ highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis’ goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.